Canada · Delayed Price · Currency is CAD Neurothera Labs Statistics
Total Valuation
Neurothera Labs has a market cap or net worth of CAD 60.25 million. The enterprise value is 66.35 million.
| Market Cap | 60.25M |
| Enterprise Value | 66.35M |
Important Dates
The next estimated earnings date is Tuesday, December 1, 2026.
| Earnings Date | Dec 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Neurothera Labs has 13.72 million shares outstanding. The number of shares has increased by 30.61% in one year.
| Current Share Class | 13.72M |
| Shares Outstanding | 13.72M |
| Shares Change (YoY) | +30.61% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | n/a |
| Float | 7.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 62.39 |
| PB Ratio | 5.73 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 68.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.25, with a Debt / Equity ratio of 0.12.
| Current Ratio | 0.25 |
| Quick Ratio | 0.23 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22.49 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -45.67% |
| Weighted Average Cost of Capital (WACC) | 3.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Neurothera Labs has paid 26,982 in taxes.
| Income Tax | 26,982 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +60.00% in the last 52 weeks. The beta is -0.11, so Neurothera Labs's price volatility has been lower than the market average.
| Beta (5Y) | -0.11 |
| 52-Week Price Change | +60.00% |
| 50-Day Moving Average | 2.82 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 49.52 |
| Average Volume (20 Days) | 5,008 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neurothera Labs had revenue of CAD 965,668 and -7.39 million in losses. Loss per share was -1.25.
| Revenue | 965,668 |
| Gross Profit | 687,328 |
| Operating Income | -5.46M |
| Pretax Income | -7.68M |
| Net Income | -7.39M |
| EBITDA | -5.20M |
| EBIT | -5.46M |
| Loss Per Share | -1.25 |
Balance Sheet
The company has 1.27 million in cash and 1.28 million in debt, with a net cash position of -9,941 or -0.00 per share.
| Cash & Cash Equivalents | 1.27M |
| Total Debt | 1.28M |
| Net Cash | -9,941 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 10.52M |
| Book Value Per Share | 0.43 |
| Working Capital | -4.24M |
Cash Flow
| Operating Cash Flow | -2.23M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 252,630 |
| Net Borrowing | 1.58M |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 71.18% |
| Operating Margin | -565.44% |
| Pretax Margin | -795.29% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Neurothera Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.61% |
| Shareholder Yield | -30.61% |
| Earnings Yield | -12.26% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 2, 2026. It was a reverse split with a ratio of 0.0714286.
| Last Split Date | Sep 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.0714286 |
Scores
Neurothera Labs has an Altman Z-Score of -2.82 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.82 |
| Piotroski F-Score | 2 |